Dr. Scott Cole, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Oklahoma College of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,357
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Oklahoma College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OK license 27620 -
Internal Medicine Physician
AL license 00026144
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Francis Hospital, Inc Tulsa, OK
- Ascension St John Medical Center Tulsa, OK
- Stillwater Medical Center Stillwater, OK
- Saint Francis Hospital Vinita, Inc Vinita, OK
- Stillwater Medical-Blackwell Blackwell, OK
Medical groups
- Stillwater Medical Center Authority (153 clinicians)
- Oklahoma Cancer Specialists and Research Institute, LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,357
- Services billed
- 217,804
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 18,000 | 24 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 15,850 | 173 |
| Injection, nivolumab, 1 mg | 12,720 | 25 |
| Injection, pembrolizumab, 1 mg | 10,000 | 27 |
| Injection, paclitaxel, 1 mg | 9,336 | 33 |
| Injection, granisetron, extended-release, 0.1 mg | 8,000 | 55 |
| Injection, oxaliplatin, 0.5 mg | 7,900 | 17 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,740 | 22 |
| Injection, aprepitant, 1 mg | 7,280 | 43 |
| Injection, lanreotide, 1 mg | 4,680 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Tulsa, OK | 462 |
| Prochlorperazine Maleate Other prescribers in Tulsa, OK | 127 |
| Ondansetron Hcl Other prescribers in Tulsa, OK | 119 |
| Exemestane | 97 |
| Anastrozole Other prescribers in Tulsa, OK | 94 |
| Levothyroxine Sodium Other prescribers in Tulsa, OK | 93 |
| Potassium Chloride Other prescribers in Tulsa, OK | 85 |
| Eliquis (apixaban) Other prescribers in Tulsa, OK | 80 |
| Levofloxacin Other prescribers in Tulsa, OK | 78 |
| Oxycodone Hcl Other prescribers in Tulsa, OK | 74 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 59 payments worth $1,535 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $280 |
|---|---|
| Daiichi Sankyo Inc. | $168 |
| Pfizer Inc. | $164 |
| Caris Mpi, Inc. | $141 |
| Novartis Pharmaceuticals Corporation | $133 |
| Tempus Ai, Inc | $119 |
| Merck Sharp & Dohme LLC | $93.08 |
| Janssen Biotech, Inc. | $61.53 |
| Food and Beverage | $1,455 |
|---|---|
| Education | $79.62 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jun 9, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Oct 22, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Oct 22, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Pfizer Inc. Jun 9, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Pfizer Inc. Oct 29, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Pfizer Inc. May 15, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Pfizer Inc. Sep 8, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Pfizer Inc. Sep 6, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Pfizer Inc. Feb 4, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $79,256 in research payments for these studies, mostly to the institutions running them.
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564
Merck Sharp & Dohme LLC - A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - K…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.